Company intelligence
Karyopharm Therapeutics Inc.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
Verified activity
Signals from Karyopharm Therapeutics Inc.
2 published signals
Legal & Regulatory
Karyopharm Therapeutics Inc. submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new treatment in frontline myelofibrosis based on results from the Phase 3 SENTRY trial presented at ASCO, EHA, and published in a peer-reviewed journal.
Reported by Karyopharm Therapeutics Inc.
Customers & Market
Karyopharm Therapeutics Inc. achieved an important milestone for MF patients and the company itself after years of hard work and dedication.
Reported by Stuart Poulton